BELLUS Health Inc. (TSE:BLU – Get Rating) – Research analysts at Jefferies Financial Group cut their FY2022 earnings per share (EPS) estimates for shares of BELLUS Health in a research note issued on Wednesday, November 16th. Jefferies Financial Group analyst S. Jeong now forecasts that the company will earn ($1.00) per share for the year, down from their prior forecast of ($0.94). The consensus estimate for BELLUS Health’s current full-year earnings is ($1.02) per share. Jefferies Financial Group also issued estimates for BELLUS Health’s Q4 2022 earnings at ($0.31) EPS, FY2023 earnings at ($1.28) EPS, FY2024 earnings at ($1.43) EPS, FY2025 earnings at ($1.04) EPS and FY2026 earnings at ($1.12) EPS.
Separately, Evercore ISI reissued a “buy” rating and set a C$24.00 target price on shares of BELLUS Health in a report on Tuesday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of C$17.40.
BELLUS Health Stock Down 1.2 %
BELLUS Health Company Profile
BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.